The recent approval of Novartis AG's Diovan/HCT and Exforge as a first-line, single pill combination for high blood pressure represents an approach to treatment that has become standard practice for many physicians - a sign that doctors are likely to embrace this latest product. (BioWorld Financial Watch) Read More
